CIK 0001754068
- Non-accelerated filer
- Smaller reporting company
Kalaris Therapeutics, Inc.
Sign in to watch- Ticker
- KLRS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 831971007
- Phone
- +1 650-249-2727
- Business address
- 400 CONNELL DRIVE, SUITE 5500, BERKELEY HEIGHTS, NJ, 07922
- Former names
- Allovir, Inc., ViraCyte, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-03 | Hallal David Director | Grant or award · Stock Option (Right to Buy) | +9,000 | 9,000 | ||
| 2025-04-10 | Hallal David Director | Grant or award · Stock Option (Right to Buy) | +18,000 | 18,000 | ||
| 2024-06-06 | Hallal David Director | Grant or award | +35,000 | 2,143,662 | ||
| 2023-05-11 | Hallal David Director | Grant or award | +35,000 | 2,108,662 | ||
| 2022-10-19 | Hallal David Director | Sale | −600,000 | $8.45 | $5.1M | 138,153 |
| 2022-09-29 | Hallal David Director | Sale | −400,000 | $7.35 | $2.9M | 720,965 |
| 2022-07-28 | Hallal David Director | Grant or award | +3,253,796 | $4.61 | $15.0M | 16,674,766 |
| 2022-07-21 | Hallal David Director | Sale | −4,227 | $5.33 | $23K | 2,073,662 |
Page 1 of 1 · 8 trades